Cytokinetics (FRA:KK3A) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KK3A Cytokinetics Inc FRA:KK3A
53 GF Score
Price €71.22
GF Value €218.59
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Cytokinetics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cytokinetics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:KK3A vs ARWR, TECH, KRYS: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Cytokinetics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Margin of Safety % (DCF FCF Based) falls into.


FRA:KK3A
53GF Score
Cytokinetics Inc FRA:KK3A
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytokinetics (FRA:KK3A) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €71.22 is trading 67.4% below its estimated GF Value™ of €218.59. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for FRA:KK3A:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €218.59 vs. price of €71.22 (67.4% below fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the FRA:KK3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
53GF Score

Get the complete analysis for FRA:KK3A

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.22
Price
€218.59
GF Value